Her scientific interests lie mostly in Internal medicine, Endocrinology, Randomized controlled trial, Ezetimibe and Placebo. She combines subjects such as Gastroenterology and Cardiology with her study of Internal medicine. Her work deals with themes such as Oncology and Study heterogeneity, which intersect with Endocrinology.
The concepts of her Ezetimibe study are interwoven with issues in Diabetes mellitus and Absolute risk reduction. Her Diabetes mellitus research focuses on subjects like Risk factor, which are linked to Mortality rate, Psychiatry, Depression, Vascular disease and Emergency medicine. Her Alirocumab research is multidisciplinary, relying on both Atorvastatin, Bococizumab, PCSK9 and Urology.
Her primary scientific interests are in Internal medicine, Statin, Women's Health Initiative, Endocrinology and Cholesterol. Her Internal medicine research incorporates elements of Diabetes mellitus and Cardiology. Her biological study spans a wide range of topics, including Guideline, Adverse effect, Secondary prevention and Intensive care medicine.
Her Women's Health Initiative research incorporates themes from Physical therapy, Gerontology, Hazard ratio, Hormone therapy and Risk factor. Her research on Risk factor frequently connects to adjacent areas such as Surgery. The Ezetimibe study combines topics in areas such as Alirocumab, Atorvastatin, PCSK9, Placebo and Simvastatin.
Her primary areas of investigation include Internal medicine, Statin, Intensive care medicine, Cohort and Ezetimibe. Her research integrates issues of Diabetes mellitus, Placebo, Guideline and Cardiology in her study of Internal medicine. Jennifer G. Robinson has researched Guideline in several fields, including Blood cholesterol and Low density lipoprotein cholesterol.
Her Statin study integrates concerns from other disciplines, such as Adverse effect, Myocardial infarction and PCSK9. Her study in PCSK9 is interdisciplinary in nature, drawing from both Alirocumab and Familial hypercholesterolemia. Her Ezetimibe study frequently links to related topics such as Evolocumab.
Jennifer G. Robinson spends much of her time researching Internal medicine, Statin, Intensive care medicine, Secondary prevention and Randomized controlled trial. Her research investigates the link between Internal medicine and topics such as Placebo that cross with problems in Diabetes mellitus and Adverse effect. Her Statin research integrates issues from Intervention, Alirocumab, Poisson regression and PCSK9.
Her Alirocumab study combines topics in areas such as Gastroenterology and Clinical endpoint. Her Intensive care medicine study combines topics from a wide range of disciplines, such as Statin therapy and Clinical trial. Her work carried out in the field of Randomized controlled trial brings together such families of science as Absolute risk reduction, Disease and Generalized estimating equation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J Stone;Jennifer G Robinson;Alice H. Lichtenstein;C Noel Bairey Merz.
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff;Donald M. Lloyd-Jones;Glen Bennett;Sean Coady.
Journal of the American College of Cardiology (2014)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson;Michel Farnier;Michel Krempf;Jean Bergeron.
The New England Journal of Medicine (2015)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
David C. Goff;Donald M. Lloyd-Jones;Faha Glen Bennett;Sean Coady.
Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association
Frank M. Sacks;Alice H. Lichtenstein;Jason H.Y. Wu;Lawrence J. Appel.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
D I Swerdlow;M V Holmes;K B Kuchenbaecker.
The Lancet (2012)
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg;Paul N. Hopkins;Peter P. Toth;Christie M. Ballantyne.
Journal of Clinical Lipidology (2011)
Loss-of-function mutations in APOC3, triglycerides, and coronary disease
Jacy Crosby;Gina M. Peloso;Gina M. Peloso;Paul L. Auer;David R. Crosslin.
The New England Journal of Medicine (2014)
Noninvasive Pulse Wave Analysis for the Early Detection of Vascular Disease
Jay N Cohn;Stanley M Finkelstein;Gary McVeigh;Dennis Morgan.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Daniel I Swerdlow;David Preiss;Karoline B Kuchenbaecker;Michael Holmes.
The Lancet (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: